Kamesh Rajendra Babu

Dr. Kamesh Rajendra Babu

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2014 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
MAMahesh Appari
Mahesh Appari
Kamesh Rajendra BabuKamesh Rajendra Babu
Kamesh Rajendra Babu
AKAdam Kaczorowski
Adam Kaczorowski
WGWolfgang Gross
Wolfgang Gross
Ingrid HerrIngrid Herr
Ingrid Herr
Pancreatic ductal adenocarcinoma (PDA) has the worst prognosis of all malignancies, and current therapeutic options do not target cancer stem cells (CSCs), which may be the reason for the extreme aggressiveness. The dietary agents sulforaphane and quercetin enriched e.g., in broccoli, and the main and best studied green tea catechin EGCG hold promise as anti-CSC agents in PDA. We examined the efficacy of additional catechins and the combination of these bioactive agents to stem cell features and miRNA signaling. Two established and one primary PDA cell line and non-malignant pancreatic ductal cells were used. Whereas each agent strongly inhibited colony formation, the catechins ECG and CG were more effective than EGCG. A mixture of green tea catechins (GTCs) significantly inhibited viability, migration, expression of MMP-2 and -9, ALDH1 activity, colony and spheroid formation and induced apoptosis, but the combination of GTCs with sulforaphane or quercetin was superior. Following treatment with bioactive agents, the expression of miR-let7-a was specifically induced in cancer cells but not in normal cells and it was associated with K-ras inhibition. These data demonstrate that sulforaphane, quercetin and GTC complement each other in inhibition of PDA progression by induction of miR-let7-a and inhibition of K-ras.

12 November 2015 in Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
Kamesh Rajendra BabuKamesh Rajendra Babu
Kamesh Rajendra Babu
MMMartina Ulrike Muckenthaler
Martina Ulrike Muckenthaler
Ferroportin (FPN) exports iron from duodenal enterocytes, macrophages, and hepatocytes to maintain systemic iron homeostasis. In addition, FPN is expressed

6 February 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Kamesh Rajendra BabuKamesh Rajendra Babu
Kamesh Rajendra Babu
MMMartina Ulrike Muckenthaler
Martina Ulrike Muckenthaler
Transferrin receptor 1 (TFR1) is a transmembrane glycoprotein that allows for transferrin-bound iron uptake in mammalian cells. It is overexpressed in various cancers to satisfy the high iron demand of fast proliferating cells. Here we show that in hepatocellular carcinoma (HCC) TFR1 expression is regulated by miR-148a. Within the TFR1 3′UTR we identified and experimentally validated two evolutionarily conserved miRNA response elements (MREs) for miR-148/152 family members, including miR-148a. Interestingly, analyses of RNA sequencing data from patients with liver hepatocellular carcinoma (LIHC) revealed a significant inverse correlation of TFR1 mRNA levels and miR-148a. In addition, TFR1 mRNA levels were significantly increased in the tumor compared to matched normal healthy tissue, while miR-148a levels are decreased. Functional analysis demonstrated post-transcriptional regulation of TFR1 by miR-148a in HCC cells as well as decreased HCC cell proliferation upon either miR-148a overexpression or TFR1 knockdown. We hypothesize that decreased expression of miR-148a in HCC may elevate transferrin-bound iron uptake, increasing cellular iron levels and cell proliferation.

Verified
Journal Article
Open access
PDF file
Kamesh Rajendra BabuKamesh Rajendra Babu
Kamesh Rajendra Babu
Yvonne TayYvonne Tay
Yvonne Tay
Reactive oxygen species (ROS) are highly reactive oxygen-containing chemical species formed as a by-product of normal aerobic respiration and also from a number of other cellular enzymatic reactions. ROS function as key mediators of cellular signaling pathways involved in proliferation, survival, apoptosis, and immune response. However, elevated and sustained ROS production promotes tumor initiation by inducing DNA damage or mutation and activates oncogenic signaling pathways to promote cancer progression. Recent studies have shown that ROS can facilitate carcinogenesis by controlling microRNA (miRNA) expression through regulating miRNA biogenesis, transcription, and epigenetic modifications. Likewise, miRNAs have been shown to control cellular ROS homeostasis by regulating the expression of proteins involved in ROS production and elimination. In this review, we summarized the significance of ROS in cancer initiation, progression, and the regulatory crosstalk between ROS and miRNAs in cancer.

13 October 2019 in RNA Biology
Verified
Journal Article
Open access
BZBin Zhang
Bin Zhang
Kamesh Rajendra BabuKamesh Rajendra Babu
Kamesh Rajendra Babu
CLChun You Lim
Chun You Lim
ZKZhi Hao Kwok
Zhi Hao Kwok
JLJia Li
Jia Li
Yvonne TayYvonne Tay
Yvonne Tay
RNA-binding proteins (RBPs) are key regulators of posttranscriptional processes such as RNA maturation, localization, turnover and translation. Despite their dysregulation in various diseases including cancer, the landscape of RBP expression in human cancer has not been well elucidated. Here, we built a comprehensive expression landscape of 1504 RBPs across 16 human cancer types, which revealed that RBPs are predominantly upregulated in tumours and this phenomenon is affected by the tumour immune subtypes and microenvironment. Across different cancer types, 109 RBPs are consistently upregulated while 41 RBPs are consistently downregulated. These up-regulated and down-regulated RBPs show distinct molecular characteristics and prognostic effects, whereas their dysregulation is mediated by distinct cis/trans-regulatory mechanisms. Finally, we validated one candidate PABPC1L that might promote colon tumorigenesis by regulating mRNA splicing. In summary, we built a comprehensive expression landscape of RBPs across different cancer types and identified consistently dysregulated RBPs which could be novel targets for developing broad-spectrum anticancer agents.

4 September 2022 in Archiv der Pharmazie
Verified
Journal Article
Closed access
SSSiddharth Singh
Siddharth Singh
DRDeepika Raina
Deepika Raina
DRDinesh Rishipathak
Dinesh Rishipathak
Kamesh Rajendra BabuKamesh Rajendra Babu
Kamesh Rajendra Babu
RKRiya Khurana
Riya Khurana
SGShraddha Manish Gupta
Shraddha Manish Gupta